Fate Therapeutics (FATE) said late Friday that preclinical data for its CAR T-cell candidate FT836 demonstrated the product's potential for durable anti-tumor activity without intervention.
The data "support the pan-cancer activity of MICA/B targeting, and indicate that our next-generation, iPSC-derived CAR T-cell platform has the potential to drive potent and durable anti-tumor activity without the need for administration of conditioning chemotherapy to deplete host immune cells," Bob Valamehr, head of research and development at Fate, said in a statement.
Fate presented the data at the annual meeting of the Society of Immunotherapy of Cancer in Houston.
FT836 combines multiple next-generation synthetic controls of CAR T-cell function including a novel "Sword & Shield" technology "to address critical challenges that have limited CAR T cell safety and efficacy in treating solid tumors," the company said.
Price: 2.47, Change: +0.05, Percent Change: +2.07
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。